The effect of anti-CGRP antibody treatment on central sensitization

The effect of anti-CGRP antibody treatment on central sensitization - The effect of anti-CGRP antibody treatment on central sensitization

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000044096

Enrollment

200

Registered

2021-05-02

Start date

2021-05-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

migraine

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)The patients treated with Galcanezumab in the course of treatment covered by health insurance 2) The patients who fulfill International Headache Classification 3rd Edition criteria of 1.1 Migraine without Aura, 1.2 migraine with Aura, and 1.3 Chronic migraine. 3) Medication overuse headache is eligible 4) Inpatients or outpatients 5) Patients with written informed consent.

Exclusion criteria

Exclusion criteria: 1) Patients with secondary headache except for medication overuse headache 2) Patients with trigeminal autonomic cephalalgias (TACs)

Design outcomes

Primary

Measure	Time frame
The improvement of central sensitization in migraine after 6 months of Galcanezumab treatment	—

Countries

Japan

Contacts

Public ContactDaisuke DANNO

Tominaga Hospital Headache center, Department of neurology

daisuke_danno@yahoo.co.jp06-6568-1601

Outcome results